Skip to content
MarketScale
‹ Back to IndustriesHealthcare

What Impact Does the Coronavirus have on Global Business?

The potentially lasting effects of the Coronavirus, like those of the early-aughts SARS outbreak and the early-2010s’ avian-flu scare, are being felt not only in China, but across the globe. Originating in Wuhan, China, a city with a population of more than 10 million people, Coronavirus has kicked off a fast-spreading epidemic in the heart…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

The potentially lasting effects of the Coronavirus, like those of the early-aughts SARS outbreak and the early-2010s’ avian-flu scare, are being felt not only in China, but across the globe.

Originating in Wuhan, China, a city with a population of more than 10 million people, Coronavirus has kicked off a fast-spreading epidemic in the heart of Chinese manufacturing.

That location has resulted in ripple effects throughout the global economy as businesses that rely on Chinese manufacturing scramble for answers and investors and forecasters have a finger on the world economy’s proverbial panic button.

What outcomes and impacts are most likely in the wake of the disease?

Manufacturing Receives a Gut Punch

Though recent trends regarding the U.S. Institute for Supply Management seemed to suggest a renewed manufacturing boom – or at least a return to growth after a lengthy slowdown, the Coronavirus outbreak has thrown a China-sized wrench squarely in the middle of that progress.

Major players across a variety of industries are feeling the effects – from the actual act of shipping goods around the world to impacts on the oil and gas, construction and steel, and automotive industries, among others, manufacturing’s contraction is almost certain to put a hefty squeeze on the world’s production and transportation capabilities.

Tech, Even Among Giants, Hit Hard

In particular, the technology sector could be left reeling from the lengthening shuttering of Chinese production.

Apple has already closed all of the company’s offices and stores in China through Sunday, and factories for both the American tech giant and other major players could follow suit depending on the continued severity of the outbreak.

Analysts at Goldman Sachs predicted a 1.6-percentage-point drop in China’s first-quarter GDP growth, and a recommendation from the U.S. Centers for Disease Control and Prevention has spurred employers as large as Microsoft, Facebook and Amazon to implement various restrictions on travel in recent days.

Like companies across all the industries impacted by the outbreak, tech companies will be left scrambling for replacement manufacturing solutions if they mean to keep up with demand and avoid skidding off the road entirely.

The Global Economy Is in Flux

China’s central bank has already pledged to pump an enormous sum of money into the country’s economy in a last-ditch attempt to head off the worst of the disease’s financial impact, and markets around the globe are reacting negatively to the uncertainty surround the outbreak.

In the U.S., stocks are rebounding as a result of this attempted stimulus, as investors saw the DOW Jones Industrial Average balloon more than 400 points to fight back against recent dips related to the disease.

If previous American market reactions to similar outbreaks, which have been largely much ado about nothing, are to be trusted, the temporary panic could subside and give way to clearer heads, more central-bank stimulation and a steadier-than-expected market.

However, should the disease continue to spread and gain a more impactful stranglehold on the Chinese economy, there’s still a very real possibility for more disruption.

For the latest news, videos, and podcasts in B2B, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512